top of page
Search

Insights from the FIGO and IMS Position Paper on Hormone Therapy for Women with Premature Ovarian Insufficiency

Updated: Aug 21

Premature ovarian insufficiency (POI) and early menopause affect a significant number of women worldwide, often leading to serious health challenges beyond the immediate symptoms. The recent joint position paper by the International Federation of Gynecology and Obstetrics (FIGO) and the International Menopause Society (IMS) offers fresh guidance on hormone therapy (HT) for these women. This article explores the key findings of the paper, the role of hormone therapy in healthy aging, new management approaches, and what these mean for healthcare providers and patients.



Understanding the FIGO and IMS Position Paper


The position paper represents a collaborative effort to update clinical recommendations on hormone therapy for women experiencing POI or early menopause, defined as menopause before the age of 45. The paper synthesizes the latest evidence on benefits, risks, and management strategies, aiming to improve long-term health outcomes.


Key findings include:


  • Hormone therapy is strongly recommended for women with POI or early menopause until the average age of natural menopause (around 50 years).

  • HT helps mitigate symptoms such as hot flashes, mood changes, and vaginal dryness, but its benefits extend far beyond symptom relief.

  • The paper emphasizes individualized treatment plans, considering each woman’s health profile and preferences.

  • New approaches suggest flexible dosing and delivery methods to optimize safety and effectiveness.


These insights reflect a growing understanding that hormone therapy is not just about managing symptoms but also about supporting overall health and quality of life.



The Importance of Hormone Therapy in Promoting Healthy Aging


Women with premature ovarian insufficiency face increased risks of osteoporosis, cardiovascular disease, cognitive decline, and mental health challenges due to early loss of estrogen. Hormone therapy plays a crucial role in addressing these risks.


Research shows that estrogen replacement in women with early menopause can:


  • Reduce bone loss and fracture risk by maintaining bone density.

  • Improve cardiovascular health by positively influencing cholesterol levels and vascular function.

  • Support cognitive function and potentially lower the risk of dementia.

  • Enhance mood and reduce anxiety and depression, improving overall well-being.


For example, a 2017 study published in Menopause found that women who started HT soon after early menopause had a 30% lower risk of heart disease compared to those who did not receive hormone therapy. This highlights the protective effect of timely HT.



New Paradigms and Approaches for Managing Hormone Therapy


The FIGO and IMS paper introduces several new concepts for managing hormone therapy in women with POI or early menopause:


  • Personalized Treatment Plans: Instead of a one-size-fits-all approach, treatment should be tailored based on age, symptoms, health risks, and patient preferences.

  • Flexible Hormone Delivery: Options include oral, transdermal patches, gels, and implants. Transdermal delivery may reduce the risk of blood clots compared to oral estrogen.

  • Extended Duration of Therapy: Women are encouraged to continue HT until the average age of natural menopause, which may mean several years of treatment.

  • Monitoring and Follow-up: Regular assessment of symptoms, bone density, cardiovascular health, and potential side effects is essential.


These approaches aim to maximize benefits while minimizing risks, ensuring women receive the most appropriate care.



Eye-level view of a healthcare professional discussing hormone therapy options with a middle-aged woman in a clinic



Potential Benefits and Risks Associated with Hormone Therapy


Hormone therapy offers many benefits but also carries some risks, which the position paper addresses clearly.


Benefits


  • Relief from menopausal symptoms such as hot flashes, night sweats, and vaginal dryness.

  • Protection against osteoporosis and fractures.

  • Improved cardiovascular health when started early.

  • Positive effects on mood, sleep, and cognitive function.

  • Enhanced quality of life and sexual health.


Risks


  • Slightly increased risk of venous thromboembolism, especially with oral estrogen.

  • Potential risk of breast cancer with prolonged use, though this risk is lower in younger women using HT for POI.

  • Possible side effects like breast tenderness, headaches, or nausea.


The paper stresses that for women with premature ovarian insufficiency, the benefits of hormone therapy generally outweigh the risks, especially when therapy is started early and monitored carefully.



Implications for Healthcare Providers and Patients


Healthcare providers should be proactive in identifying women with POI or early menopause and discussing hormone therapy options openly. Key actions include:


  • Early diagnosis and counseling: Educate women about the health risks of early menopause and the role of HT.

  • Shared decision-making: Involve patients in choosing the type, dose, and duration of hormone therapy.

  • Regular monitoring: Track bone health, cardiovascular markers, and symptom control.

  • Addressing barriers: Help women overcome fears or misconceptions about hormone therapy.


For patients, understanding the importance of hormone therapy can empower them to seek appropriate care and maintain their health. Women who have experienced early menopause should consult their healthcare providers about hormone therapy options and follow-up plans.



The joint FIGO and IMS position paper marks a significant step forward in managing hormone therapy for women with premature ovarian insufficiency or early menopause. By emphasizing personalized care, extended treatment duration, and a clear understanding of benefits and risks, it supports healthier aging and improved quality of life for these women. If you or someone you know is affected by early menopause, discussing hormone therapy with a healthcare professional can be a vital step toward long-term health and well-being.


Disclaimer: This article is for informational purposes only and does not replace professional medical advice. Always consult a healthcare provider for personalized recommendations.


Comments

bottom of page